

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

ASX Release

AVEXA APPOINTS STEPHEN KERR AS CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

Melbourne, Australia, 10th March 2009: Avexa Limited ("Avexa") (ASX: AVX) today announced the appointment of Mr Stephen Kerr as Chief Financial Officer (CFO) and Company Secretary. Mr Kerr will commence in the role on 16 March 2009.

"We are very pleased to have Stephen join Avexa as a key member of our executive team. His strong track record of achievement and experience from a wide range of organizations will be instrumental in moving Avexa forward during this exciting time in the company's history," said Julian Chick, PhD, Chief Executive Officer.

Stephen Kerr has more than 25 years experience in finance, most recently as CFO and Company Secretary at life science company Optalert Pty Ltd. Prior to that, he worked with the Tolhurst Group Limited managing a variety of projects including merger and acquisition transactions and capital raisings. Mr Kerr commenced his career in chartered accounting before moving into the corporate environment. He has held senior management positions in finance with a number of public and private companies in Australia and New Zealand including Freightways Limited (NZ) and ASX listed Ausdoc Group Limited. A qualified Chartered Accountant since 1987, Mr Kerr is also a Fellow of the Chartered Institute of Company Secretaries of Australia. He received his Bachelor of Commerce from Melbourne University.

"Avexa is a promising company with exciting drug development programs, and I am very happy to be joining the company at this time," stated Mr Kerr. "I am looking forward to the next stage in the company's growth, particularly the successful completion of the Phase III trials and subsequent launch of apricitabine."

About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including apricitabine (ATC), its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is ATC, an anti-HIV drug that has successfully completed the 48 week dosing of its Phase IIb trial and is currently in Phase III trials worldwide. www.avexa.com.au

For more information:

Avexa
Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

AU: Investor Relations

US: Investor Relations

For personal use only



A V E X A

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

Sabrina Antoniou
Blueprint Life Science Group
+ 61 2 9519 5537

Remy Bernarda
Blueprint Life Science Group
+ 1 415 375 3340 x2022

For personal use only